Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2?-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Linear covalently closed vectors, and compositions and methods for making same.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Linear covalently closed vectors, and compositions and methods for making same.

Abstract: Nucleic acid expression systems for delivery of oligonucleotides, such as RNA oligonucleotides, to target cells and methods of using the same are provided herein. Exemplary nucleic acid expression systems for expression of a payload sequence include at least one composition that delivers an inhibitor of a NF-?B pathway and/or an inhibitor of an IRF pathway. Provided herein are also pharmaceutical compositions that deliver an inhibitor of a NF-?B pathway and/or an inhibitor of an IRF pathway, and methods of using the same for enhancing expression of an oligonucleotide, such as an RNA oligonucleotide.

Abstract: Compositions and methods for synthesizing an RNA product are provided herein. For example, the present disclosure provides a method of producing an RNA product comprising incubating an in vitro transcription mixture, thereby producing an RNA product that comprises a plurality of single-stranded RNA molecules. In some embodiments, an in vitro transcription mixture comprises a DNA template comprising an RNA polymerase promoter sequence operatively linked to a target sequence; at least one RNA polymerase that recognizes the RNA polymerase promoter sequence; a plurality of ribonucleotides comprising at least two different types of ribonucleotides, each type comprising a different nucleoside; and a transcription buffer comprising an osmolyte.

Abstract: Nucleic acid expression systems for delivery of RNA oligonucleotides to target cells and methods of using the same are provided herein. For example, in some embodiments, a nucleic acid expression system comprises: (i) an RNA oligonucleotide comprising a payload sequence (e.g., a Myc inhibitor), and (ii) an RNA oligonucleotide comprising a sequence that encodes a US11 polypeptide. Provided herein are also pharmaceutical compositions comprising an RNA oligonucleotide comprising a payload sequence that encodes a dominant negative variant of a Myc polypeptide or portions thereof, and a pharmaceutically acceptable carrier.

Abstract: In an example, there is disclosed a network apparatus for providing native load balancing within a switch or router, including a first network interface operable to communicatively couple to a first network; a plurality of second network interfaces operable to communicatively couple to a second network; one or more logic elements comprising a switching engine operable for providing network switching or routing; and one or more logic elements forming a load balancing engine operable for receiving incoming network traffic via the first network, the incoming traffic having a destination internet protocol address (IP) corresponding to a virtual IP (VIP) designated for load balancing; assigning the incoming traffic to a traffic bucket associated with the second network; and logging the assigning; wherein the switching engine and load balancing engine are configured to be provided on the same hardware as each other and as the first network interface and plurality of second network interface.

Abstract: Nucleic acid expression systems are provided herein that include a first synthetic oligonucleotide comprising a payload sequence and a second synthetic oligonucleotide comprising a sequence that encodes a helper polypeptide. Compositions (e.g., pharmaceutical compositions) comprising the nucleic acid expression systems as well as methods of using the same are also provided herein.

Abstract: Linear covalently closed vectors, and compositions and methods for making same.

Abstract: In an example, there is disclosed a network apparatus for providing native load balancing within a switch or router, including a first network interface operable to communicatively couple to a first network; a plurality of second network interfaces operable to communicatively couple to a second network; one or more logic elements comprising a switching engine operable for providing network switching or routing; and one or more logic elements forming a load balancing engine operable for receiving incoming network traffic via the first network, the incoming traffic having a destination internet protocol address (IP) corresponding to a virtual IP (VIP) designated for load balancing; assigning the incoming traffic to a traffic bucket associated with the second network; and logging the assigning; wherein the switching engine and load balancing engine are configured to be provided on the same hardware as each other and as the first network interface and plurality of second network interface.

Abstract: In an example, there is disclosed a network apparatus for providing native load balancing within a switch or router, including a first network interface operable to communicatively couple to a first network; a plurality of second network interfaces operable to communicatively couple to a second network; one or more logic elements comprising a switching engine operable for providing network switching or routing; and one or more logic elements forming a load balancing engine operable for receiving incoming network traffic via the first network, the incoming traffic having a destination internet protocol address (IP) corresponding to a virtual IP (VIP) designated for load balancing; assigning the incoming traffic to a traffic bucket associated with the second network; and logging the assigning; wherein the switching engine and load balancing engine are configured to be provided on the same hardware as each other and as the first network interface and plurality of second network interface.

Abstract: A method is provided in one example embodiment and includes transmitting from an appliance connected to a first virtual device context (“VDC”) instantiated on a network device a request for statistics associated with selected ones of a plurality of VDCs implemented on the network device, wherein the plurality of VDCs includes the first VDC and wherein the appliance is connected to the first VDC via a management link; and receiving at the appliance the requested statistics associated with the plurality of VDCs. The method may further comprise receiving at the appliance a configuration message, wherein the configuration message identifies at least one of the selected ones of the plurality of VDCs for which statistics are to be provided, at least one type of statistic to be provided for the selected ones of the VDCs, and a polling interval at which statistics are to be collected from the selected VDCs.